Abstract Number: 2709 • 2019 ACR/ARP Annual Meeting
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index
Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis and psoriatic arthritis. It is not licensed for juvenile patients yet. As biologic agents up…
ACR Meeting Abstracts